In-silico drug-likeness analysis, ADME properties, and molecular docking studies of cyanidin-3-arabinoside, pelargonidin-3-glucoside, and peonidin-3-arabinoside as natural anticancer compounds against acting receptor-like kinase 5 receptor. Issue 6 (23rd March 2022)
- Record Type:
- Journal Article
- Title:
- In-silico drug-likeness analysis, ADME properties, and molecular docking studies of cyanidin-3-arabinoside, pelargonidin-3-glucoside, and peonidin-3-arabinoside as natural anticancer compounds against acting receptor-like kinase 5 receptor. Issue 6 (23rd March 2022)
- Main Title:
- In-silico drug-likeness analysis, ADME properties, and molecular docking studies of cyanidin-3-arabinoside, pelargonidin-3-glucoside, and peonidin-3-arabinoside as natural anticancer compounds against acting receptor-like kinase 5 receptor
- Authors:
- Kurter, Hasan
Mert-Ozupek, Nazli
Ellidokuz, Hulya
Calibasi-Kocal, Gizem - Abstract:
- Abstract : Background: The aim of the study was in-silico drug-likeness analysis, absorption, distribution, metabolism, and excretion (ADME) properties, and molecular docking studies of anthocyanins as natural anticancer compounds against acting receptor-like kinase 5 (ALK5) receptor. Transforming growth factor-β (TGF-β) plays an essential role in various cellular processes. Increased expression of TGF-β and its receptor TGFβR-I (i.e. ALK5) have been associated with poor prognosis in cancer patients. Methods: The drug-likeness activity of anthocyanins was performed using SwissADME tool. Molecular docking studies were carried out by using the Autodock Vina 1.5.6 tool. Results: The results revealed that cyanidin-3-arabinoside (C3A), pelargonidin-3-glucoside (P3G), and peonidin-3-arabinoside (P3A) were able to use both Lipinski's rule of five and Ghose variations. The binding energies of C3A, P3G, and P3A against ALK5 were found as −8.0, −8.3, and −8.4 kcal mol −1, respectively. Conclusion: These selected anthocyanins have shown higher binding energies than known inhibitors to the ALK5 receptor. Further in-vitro and in-vivo studies were strongly recommended to clarify the whole mechanism.
- Is Part Of:
- Anti-cancer drugs. Volume 33:Issue 6(2022)
- Journal:
- Anti-cancer drugs
- Issue:
- Volume 33:Issue 6(2022)
- Issue Display:
- Volume 33, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 33
- Issue:
- 6
- Issue Sort Value:
- 2022-0033-0006-0000
- Page Start:
- 517
- Page End:
- 522
- Publication Date:
- 2022-03-23
- Subjects:
- ALK5 -- Anthocyanins -- molecular docking -- peonidin-3-arabinoside, SwissADME -- transforming growth factor-beta signaling pathway
Antineoplastic agents -- Periodicals
Cancer -- Chemotherapy -- Periodicals
Antineoplastic Agents -- therapeutic use -- Periodicals
Drug Therapy -- Periodicals
616.994061 - Journal URLs:
- http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00001813-000000000-00000 ↗
http://ovidsp.tx.ovid.com/spb/ovidweb.cgi ↗
http://www.anti-cancerdrugs.com/ ↗
http://journals.lww.com/pages/default.aspx ↗
http://firstsearch.oclc.org ↗ - DOI:
- 10.1097/CAD.0000000000001297 ↗
- Languages:
- English
- ISSNs:
- 0959-4973
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1547.287300
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 26872.xml